Danaher (DHR) acquires Abcam for $5.7 billion, thus adding to its Life Sciences portfolio. This move will facilitate the mapping of complex diseases and expedite the drug discovery process.
ITT to benefit from strength in the aftermarket business within the Industrial Process segment. Also, the company's measures to reward its shareholders are encouraging.
Markel (MKL) is well-poised to gain from improved pricing, effective risk management, strategic buyouts solid capital position and favorable growth estimates.